ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference
PROKWINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that ProKidney’s CEO, Bruce Culleton, M.D., will present at the 44th Annual J.P. Morgan Healthcare Conference. The ProKidney management team will also host one-on-one meetings throughout the event.
ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference
PROKWINSTON-SALEM, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in September:
ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
PROKWINSTON-SALEM, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapeutics company focused on chronic kidney disease (CKD), today reported financial results for the second quarter ended June 30, 2025, and provided regulatory and clinical updates.
ProKidney Q1 EPS $(0.13) Beats $(0.16) Estimate, Sales $230.00K
PROKProKidney FY 2024 GAAP EPS $(0.62) Misses $(0.57) Estimate, Ended The Fourth Quarter With $358M In Cash And Cash Equivalents And Marketable Securities, Supporting Operations Into Mid-2027
PROKTop 3 Health Care Stocks You'll Regret Missing This Quarter
PROK